Trialsorforgliproneli lillyperipheral artery diseaseclinicaltrials.gov

Lilly begins Phase 3 trial of orforglipron in peripheral artery disease

The randomized, double-blind, placebo-controlled study enrolls patients with Fontaine II PAD and runs about 58 weeks per participant.

By Priya Raman · Science Reporter

Oct 8 08:00 ETSource: ClinicalTrials.gov

The wire

01Eli Lilly registered NCT07223593, a Phase 3 randomized, double-blind, placebo-controlled trial of once-daily oral orforglipron in participants with Fontaine II peripheral arterial disease, with a start date of 31 October 2025 and recruiting status.
02The trial pushes the oral GLP-1 agonist beyond diabetes and obesity into a vascular indication, a signal of where Lilly sees label expansion for its non-peptide incretin candidate.
03Participation lasts roughly 58 weeks; the registry entry does not disclose enrollment target, dose levels or primary endpoint details.

From the source

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593 · PHASE3 · RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Peripheral Arterial Disease.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07223593